Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • GBMA Executive and Board
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
        • 2022
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • International Generic and Biosimilar Medicines Association (IGBA)
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2023
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Extended Strategic Agreement

Extended Strategic Agreement

The Generic Medicines Industry Association (GMiA) has signed a Strategic Agreement with the Australian Government to support the ongoing supply of affordable generic and biosimilar medicines in Australia and deliver a five year period of certainty for the industry that provides them. This agreement has now been extended by a further two year period. The extension document can be accessed at the bottom of this page.

The Agreement recognises the essential role of generic medicines and biosimilars in delivering affordable healthcare through the Pharmaceutical Benefits Scheme (PBS). It also recognises the significant savings that continue to be delivered by generic medicines and biosimilars, first by providing competition and then through price disclosure.

“Every time a patient or healthcare professional uses a generic medicine or a biosimilar it saves money that can be used to pay for newer PBS medicines. GMiA members have, and continue to, deliver billions of dollars in PBS savings,” said Mark Crotty, GMiA Chairman (2015).

“GMiA and the Government have a common interest in the ongoing and reliable access to affordable generic medicines and biosimilars, a strong PBS that can meet the current and future needs of Australians, and having a sustainable generic medicines sector,” he said.

The Strategic Agreement is the result of constructive and respectful dialogue between the GMiA and the Government over the past three months and is the first strategic agreement GMiA has signed with the Australian Government. It states that both parties will work together to identify and implement initiatives to support the ongoing sustainability of the generic medicines sector, undertaken as part of a “sustainability initiative” between the Commonwealth and GMiA.

The Agreement states that no further price-related changes will be made to the F2 formulary, and that the Department of Health and GMiA will work collaboratively to identify, and resolve quickly, any unintended consequences of budget savings particularly where they may impact on the reliable supply of vital, affordable medicines for Australian patients.

Through this Strategic Agreement, GMiA will also work to ensure that Australia can realise the full benefits of biosimilars. GMiA will continue to work with the Government on initiatives to encourage biosimilar uptake as well as a $20 million national education campaign to increase doctor and consumer awareness and understanding of biosimilars.

 

 

GMiA Strategic Agreement                     Strategic Agreement Extension

 

 

Our Members

Sandoz Logo
Sandoz Logo Sandoz Blue RGB
PRIMARY_neo_health_logo_RGB[86]
PRIMARY_neo_health_logo_RGB[86]
logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Gedeon_Richter_HOR_CMYK-01
Gedeon_Richter_HOR_CMYK-01
Juno
Juno
Teva
Teva
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
CommEyes_Logo_Full (3)
CommEyes_Logo_Full (3)
sinapse
sinapse
PearceIP-Masterbrand-CMYK-tag
PearceIP-Masterbrand-CMYK-tag

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

IGBA’s Annual Global Biosimilars Week Focuses on Oncology Care

November 14, 2023

Tuesday, November 14, 2023 Geneva, Switzerland In the week … More...

Neo Health joins GBMA under new membership tier

September 28, 2023

Thursday, September 28, 2023 Canberra, … More...

GBMA welcomes Teva Pharma to its growing membership base

July 24, 2023

Tuesday July 25, 2023 Canberra, … More…

© 2023 Generic and Biosimilar Medicines Association Pty Ltd | Privacy Policy | Contact Us